Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0

作者：

Giri, Pratyush

Patil, Sushrut

Ratnasingam, Sumita

Prince, H. Miles

Milliken, Samuel

Meijide, Javier Briones

Coyle, Luke

Van der Poel, Marjolein

Mulroney, Carolyn M.

Farooqui, Mohammed Z. H.

Wong, Hansen

Desai, Rajendra

Zugmaier, Gerhard

Mergen, Noemi

Cannell, Paul

机构：

[1] Royal Adelaide Hosp, Adelaide, SA, Australia

[2] Alfred Hosp & Monash Univ, Melbourne, Vic, Australia

[3] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia

[4] Epworth Healthcare, East Melbourne, Australia

[5] Sir Peter MacCallum Canc Inst, East Melbourne, Australia

[6] St Vincents Hosp, Darlinghurst, NSW, Australia

[7] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

[8] Royal Northshore Hosp, St Leonards, NSW, Australia

[9] Maastricht Univ, GROW Sch Oncol & Dev Biol, Div Hematol, Dept Internal Med,Med Ctr, Maastricht, Netherlands

[10] Univ Calif San Diego, La Jolla, CA USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Amgen Clin Pharmacol Modeling & Simulat, South San Francisco, CA USA

[13] IQVIA Inc, Biostat Sci, Mumbai, India

[14] Amgen Res Munich GmbH, Munich, Germany

[15] Royal Perth Hosp, Dept Med, Perth, WA, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

19584

引用

页数：1

共 50 条

[21] A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage
Toubai, Tomomi
Kuroda, Junya
Suehiro, Youko
Mishima, Yuko
Sunami, Kazutaka
Kato, Koji
Uoshima, Nobuhiko
Kumode, Takahiro
Ota, Ai
Mitsuki, Kaori
Yokota, Daisuke
Sano, Yuri
Terui, Yasuhito
BLOOD, 2023, 142
[22] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle Limei
Prince, H. Miles
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tran-Der Tan
Ayyappan, Sabarish
Gutierrez, Antonio
Li, Jingjin
Ufkin, Melanie
Zhu, Min
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Walewski, Jan
BLOOD, 2022, 140 : 1070 - 1071
[23] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
Van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Marie Jose
Schuster, Stephen J.
Salles, Gilles Andre
Maziarz, Richard Thomas
Anak, Oezlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
BLOOD, 2017, 130
[24] Blinatumomab in relapsed/refractory diffuse large B cell lymphoma
Van Dijck, Ruben
Janssens, Ann
Dierickx, Daan
Delforge, Michel
Gheysens, Olivier
Tousseyn, Thomas
Verhoef, Gregor
ANNALS OF HEMATOLOGY, 2017, 96 (10) : 1759 - 1762
[25] Blinatumomab in relapsed/refractory diffuse large B cell lymphoma
Ruben Van Dijck
Ann Janssens
Daan Dierickx
Michel Delforge
Olivier Gheysens
Thomas Tousseyn
Gregor Verhoef
Annals of Hematology, 2017, 96 : 1759 - 1762
[26] Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R)
Hernandez-Ilizaliturri, F. J.
Deeb, G.
Zinzani, P. L.
Pileri, S. A.
Malik, F.
Macon, W. R.
Witzig, T. E.
Goy, A.
Czuczman, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
Strati, Paolo
Kim, Tae Min
Danilov, Alexey, V
Cheah, Chan Y.
Yoon, Dok Hyun
Jurczak, Wojciech
Sharma, Shringi
Yoon, Jeong Lim
Arduini, Serena
Saeh, Jamal
Olsson, Richard F.
Gregory, Gareth
BLOOD, 2022, 140 : 6656 - 6658
[28] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Zhu, Jun
Song, Yuqin
Guo, Ye
Zhou, Keshu
Li, Wenyu
Yang, Yu
Cai, Qingqing
Wang, Zhao
Yang, Haiyan
BLOOD, 2023, 142
[29] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish
Kim, Won Seog
Kim, Tae Min
Walewski, Jan
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle
Oh, Sung Yong
Lim, Francesca Lorraine Wei Inng
Carpio, Cecilia
Tan, Tran-Der
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ufkin, Melanie
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Prince, H. Miles
BLOOD, 2023, 142
[30] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
Maziarz, Richard T.
Schuster, Stephen J.
Romanov, Vadim V.
Rusch, Elisha S.
Signorovitch, James
Ericson, Solveig G.
Maloney, David G.
Locke, Frederick L.
BLOOD, 2018, 132

← 1 2 3 4 5 →